CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV
12 March 2021. Related: Conference reports, COVID-19: treatment access, COVID-19: investigational drugs, COVID-19.
2021
CROI 2021: Community challenge 6-month CROI pay wall – rather than usual open access…
12 March 2021. Related: Conference reports, Other news.
CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission
12 March 2021. Related: Conference reports, HIV prevention and transmission.
CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial
12 March 2021. Related: Conference reports, Treatment strategies.
CROI 2021: HIV capsid uncoats in the CD4 nucleus rather than the cytoplasm – viral lifecycle updated…
12 March 2021. Related: Conference reports, Virology.
CROI 2021: Community HIV cure workshops online
12 March 2021. Related: Conference reports, Cure-related research.
Chronic kidney disease (CKD) in HIV positive people linked to time with low CD4 count: partly reversible after effective ART
12 March 2021. Related: Side effects, Coinfections and complications.
Janssen/J&J vaccine against COVID-19 is approved in the EU
12 March 2021. Related: COVID-19: vaccine research, COVID-19.
Baricitinib improves recovery in sub-group of adults hospitalised COVID-19: results from ACTT-2 study
12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
Ivermectin has no impact in treating mild COVID-19 in 400 adults in Columbia
12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
No benefit from BRII and GSK monoclonal antibodies against COVID-19 in ACTIV-3 study
12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
HTB: no.3 – plus HIV and COVID-19 (12 March 2021)
12 March 2021. Related: PDFs.
HTB: no. 2 – plus HIV and COVID-19 (24 February 2021)
24 February 2021. Related: Editorial.
In memory: Elias Phiri – community HIV and TB advocate
24 February 2021. Related: In memory.
In memory: Dr Joseph Sonnabend – pioneer HIV activist and researcher
24 February 2021. Related: In memory.
Timothy Ray Brown: a virtual memorial
24 February 2021. Related: In memory.
R4P virtual conference (2021)
24 February 2021. Related: Conference reports, HIV prevention and transmission.
VRC01 antibody only prevents minority of HIV infections: AMP study results
24 February 2021. Related: Conference reports, HIV prevention and transmission.
Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS)
24 February 2021. Related: Conference reports, Paediatric care, HIV prevention and transmission.
Promising data for multipurpose technologies to prevent HIV and pregnancy
24 February 2021. Related: Conference reports, Pregnancy, HIV prevention and transmission.
12th International Workshop on HIV paediatrics
24 February 2021. Related: Conference reports.
New LPV/r-based fixed dose HIV combination for young children: first results with Quadrimune 4-in-1
24 February 2021. Related: Conference reports, Paediatric care.
UK study for people with triple-class drug resistance
24 February 2021. Related: Drug resistance, Research studies.
Community murals in Soweto on dolutegravir-based ART: an i-Base collaboration
24 February 2021. Related: Treatment advocacy.
HIV positive people in the UK now elligible for COVID vaccinations – and to become available at HIV clinics
24 February 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: vaccine research, COVID-19: treatment access, COVID-19.
What are the main COVID-19 variants? How can they affect vaccine responses?
24 February 2021. Related: COVID-19: vaccine research, COVID-19: transmission & prevention, COVID-19.
Novavax: >90% efficacy in UK but 60% in South Africa, hints of lower effect in HIV positive participants
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
Russian Sputnik vaccine reports 91% efficacy at 21 days after the first dose
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
Janssen vaccine reports efficacy after single injection: FDA decision imminent
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
Oxford/AZ vaccine might still prevent severe COVID-19 from B.1.351 variant: supports continued used in South Africa
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
Unprecedented rapid speed of COVID vaccine development
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
WHO online vaccine tracker
24 February 2021. Related: COVID-19: vaccine research, COVID-19.
COVID-19 vaccine pricing: a BBC guide
24 February 2021. Related: COVID-19: vaccine research, COVID-19: treatment access, COVID-19.
High rates of undocumented COVID-19 mortality in Zambia without testing challenges the idea that Africa has been spared
24 February 2021. Related: COVID-19: treatment access, COVID-19: pathogenesis.
Tocilizimab effectively reduces COVID-19 related deaths and hospitalisation time: additive benefit with dexamethasone
24 February 2021. Related: COVID-19: investigational drugs, COVID-19.
Bamlanivimab (LY-CoV555) prophylaxis prevents COVID-19 in care homes: results of BLAZE-2 study
24 February 2021. Related: COVID-19: investigational drugs, COVID-19.
US FDA specifies high antibody titre for convalescent plasma and to only use in early COVID-19
24 February 2021. Related: COVID-19: investigational drugs, COVID-19.
No benefit from convalescent plasma in UK RECOVERY study: limited results restrict implications for COVID-19
24 February 2021. Related: COVID-19: investigational drugs, COVID-19.
UK variant B.1.1.7 linked to higher risk of death and hospitalisation from COVID-19
24 February 2021. Related: COVID-19: pathogenesis, COVID-19.
HTB no 2 – plus HIV and COVID-19 (24 February 2021)
24 February 2021. Related: PDFs.
HTB: no. 1 – plus HIV and COVID-19 (22 January 2021)
22 January 2021. Related: Editorial.
BHIVA 2020 virtual conference now online
22 January 2021. Related: Conference reports.
U=U is supported by a single undetectable viral load in the context of good adherence
22 January 2021. Related: Conference reports, HIV prevention and transmission.
Selected plenary talks and workshops from BHIVA 2020
22 January 2021. Related: Conference reports, On the web.
US FDA approves long-acting injectable HIV treatment: monthly dosing
22 January 2021. Related: Antiretrovirals.
Long-acting injectable HIV treatment approved in the EU: includes two-monthly dosing
22 January 2021. Related: Antiretrovirals.
Fostemsavir approved in the EU (Rukobia): NICE deferred in the UK
22 January 2021. Related: Antiretrovirals.
PHE report on HIV and STIs during COVID-19
22 January 2021. Related: HIV prevention and transmission.
Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study
22 January 2021. Related: Treatment strategies, Drug resistance.
Significant increases in LGV in gay men from 2017 to 2019: latest PHE report
22 January 2021. Related: Coinfections and complications, Other news.
HIV criminalisation during 2020: cases continue but also legal advances
22 January 2021. Related: Other news.
NICE issue UK guidelines on long COVID
22 January 2021. Related: COVID-19: guidelines, COVID-19.
BHIVA and EACS update HIV as a higher risk for COVID-19: supports priority vaccine (January 2021)
22 January 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
Recent studies on HIV and COVID-19 coinfection
22 January 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
Very low-level HIV viraemia might continue after COVID-19
22 January 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19: pathogenesis, COVID-19.
Pfizer COVID-19 vaccine might still overcome UK and SA variants
22 January 2021. Related: COVID-19: vaccine research, COVID-19.
Novavax phase 3 vaccine study launched in the UK, South Africa, US, Mexico and Puerto Rico
22 January 2021. Related: COVID-19: vaccine research, COVID-19.
Merck/MSD withdraws two vaccine candidates from further research but continues focus on treatment
22 January 2021. Related: COVID-19: vaccine research, COVID-19: investigational drugs, COVID-19.
Oral colchicine reduces hospitalisation in international randomised phase 3 outpatient study
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.
IL-6 agonists tocilizumab and sarilumab reduces mortality in severe COVID-19: interim results from REMAP-CAP study
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.
Two different dual antibody treatments each reduce SARS-CoV-2 viral load by >0.5 log
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.
IV methylprednisolone pulse treatment for hospitalised severe COVID-19
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.
Monoclonal antibody bamlanivimab is not effective in advanced COVID-19: lack of early signal stops study early
22 January 2021. Related: COVID-19: investigational drugs, COVID-19.